<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910258</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-MF</org_study_id>
    <nct_id>NCT02910258</nct_id>
  </id_info>
  <brief_title>Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis</brief_title>
  <acronym>PEG-MF</acronym>
  <official_title>Etude de l'efficacité et de la tolérance de l'interféron-pégylé Dans Les myélofibroses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who carried primary or secondary myelofibrosis from Philadelphia negative MPNs
      (PMF/SMF) and who are treated or are about to be treated with pegylated-interferon (mostly
      α2a) are eligible to this prospective study. Biological and clinical parameters will be
      collected from the beginning of the drug use until last news.

      A non-opposition consent form need to be signed before entering this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all centres interested, patients who were diagnosed for PMF/SMF can be treated with oral
      or sub-cutaneous drugs in order to reduce clinical symptoms and biological abnormalities
      belonging to these diseases.

      Pegylated-interferon is one of the better weapons that can be used in these cases. These
      treatments are well known and used from many years in french hematological centres.

      The investigators to collect clinical and biological data from patients treated with
      pegylated-interferon α2a (the most use) in case of PMF/SMF in order to assess efficacity and
      tolerance to this drug. The prescription of the product and the dose are under the
      responsibility of each practician.

      Clinical data collected: disease and patients characteristics at the time of diagnosis and at
      the beginning of the drug use, spleen and liver size, presence of constitutive symptoms,
      transfusion needs.

      Biological data collected: complete hemogram, CD34+ cells count, allele burden of JAK2V617F
      and calreticulin clones if DNA samples are collected.

      These data will be collected avery 3 months during the two first years and every 6 months
      after.

      The investigators also recorded adverse side effects if significative, the concomitant use of
      hematological drugs (cytoreductive treatments, ASE...), modalities of prescription of the
      drugs and the reason for stopping the drug and etiology of death if happened.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficiency of the interferon in Myelofibrosis</measure>
    <time_frame>Evaluation at 1 year</time_frame>
    <description>Evaluation on the presence or not of splenomegaly and physical signs or the normalization of blood counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of survival of patients with Myelofibrosis under interferon</measure>
    <time_frame>Evaluation at 5 years</time_frame>
    <description>Patients dead or alive at this time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Interferon</measure>
    <time_frame>Evaluation at 1 year</time_frame>
    <description>Presence or not of psychiatric symptoms, cramps, hepatitic abnormalities</description>
  </secondary_outcome>
  <enrollment type="Actual">62</enrollment>
  <condition>Myelofibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed for PMF or SMF and treated with pegykated interferon α2a
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary or secondary Myelofibrosis

          -  Prescription of pegylated interferon α2a

          -  Age &gt; 18 years-old

        Exclusion Criteria:

          -  Other MPNs treated with pegylated interferon α2a

          -  Patients treated for PMF or SMF but without pegylated interferon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Ianotto, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>LE Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH des pays de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29672</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIC de Cornouaille</name>
      <address>
        <city>Quimper</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelofibrosis</keyword>
  <keyword>pegylated interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

